iNtRON Biotechnology completes issuance of 3 billion KRW 9th convertible bonds, potential dilution upon conversion
iNtRON Biotechnology finalized the issuance of its 9th unregistered unsecured private convertible bonds worth 3 billion KRW with payment completed on July 15, 2026.
As these bonds are unlisted private placements, future conversion into new shares could dilute existing shareholders' equity, posing structural risk.
Although the exact conversion price and number of shares are undisclosed, based on the current market price, potential dilution is estimated at approximately 3.88%, indicating a moderate impact.
[AI Summary]iNtRON Biotechnology has completed the issuance of 3 billion KRW in 9th series convertible bonds. Without disclosed use of proceeds, capital allocation efficiency remains unclear, but the potential equity dilution of around 3.88% may weigh on short-term share price.